Key Highlights

  • Loss per share from continuing operations was USD 0.04, against USD 0.05.
  • Net loss of USD 4.94 million replaced Net Income of USD 50.49 million.
  • Loss from operations narrowed to USD 1.64 million from USD 2.06 million.
  • Cash and cash equivalents were USD 580 thousand on September 30, 2026.

BeyondSpring (NASDAQ:BYSI) lost USD 4.94 million in the third quarter of 2026, where the prior-year quarter brought net income of USD 50.49 million. The loss per share from continuing operations was USD 0.04, against USD 0.05. Over the nine months ended September 30, 2026, the net loss was USD 8.42 million, against net income of USD 38.12 million.

Operating Lines

The loss from operations was USD 1.64 million, against USD 2.06 million. Research and Development expenses were USD 968 thousand, against USD 1.11 million, and general and administrative expenses were USD 672 thousand, against USD 956 thousand.

For the nine months, the loss from operations was USD 5.86 million, against USD 5.75 million. Research and development expenses were USD 2.67 million, against USD 3.07 million, and general and administrative expenses were USD 3.19 million, against USD 2.67 million. The filing also reports a net loss attributable to noncontrolling interests from discontinued operations of USD 3.40 million for the quarter, against USD 300 thousand.

Cash and cash equivalents were USD 580 thousand at September 30, 2026, against USD 2.97 million at December 31, 2025, and short-term investments were USD 1.00 million at December 31, 2025. The filing puts the accumulated Deficit at USD 360.65 million and net current liabilities at USD 3.33 million as of September 30, 2026.

The Nasdaq Notice and the Financing Agreement

On September 17, 2026, the filing says, the Listing Qualifications Department of The Nasdaq stock market notified the company in writing that its ordinary shares had closed below USD 1.00 per share for 30 consecutive Business days. The company has until March 16, 2027 to regain compliance with the bid price requirement and may qualify for a further 180-calendar-day period, at the discretion of Nasdaq staff.

On September 29, 2026, the company signed a sales agreement with Citizens JMP Securities, which will act as agent in selling up to 9,200,000 ordinary shares in an at-the-market offering program.

The SEED Therapeutics Divestiture

The filing records that in January 2025 the company signed definitive agreements with three investors to sell part of its Series A-1 Preferred Shares of SEED Therapeutics. Under those agreements, a third closing of 3,500,128 shares for about USD 14.88 million is due no later than December 15, 2026. On December 13, 2024, the board approved a plan to divest approximately 90% to 100% of the company's interests in SEED.

The Quarter in Brief

BeyondSpring reported a net loss of USD 4.94 million and a loss per share from continuing operations of USD 0.04. Cash and cash equivalents were USD 580 thousand at September 30, 2026.